Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Relative Bioavailability of Oxymorphone 40 mg Extended-Release Tablets (Sandoz, Inc.) Compared to Opana ER (Oxymorphone Hydrochloride) Extended-Release Tablets, 40 mg (Endo Pharmaceuticals, Inc.) in Healthy Volunteers Under Fasted Conditions

NCT00857428 is registered in ClinicalTrials.gov with Sandoz as lead sponsor.

NCT NCT00857428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00857428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Relative Bioavailability of Oxymorphone 40 mg Extended-Release Tablets (Sandoz, Inc.) Compared to Opana ER (Oxymorphone Hydrochloride) Extended-Release Tablets, 40 mg (Endo Pharmaceuticals, Inc.) in Healthy Volunteers Under Fasted Conditions
Lead sponsor
Sandoz
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2007
Completion date
December 31, 2007
Enrollment
50 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pain